louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06185153: Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections
Official title: Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections - A Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Carbapenemase-Producing Enterobacteriaceae
Keywords: Carbapenemase
Enterobacteriaceae
VIM-producing strains
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2023-12-29
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: - Adult patient (≥18) treated at the HUS for a VIM-producing enterobacteria infection between 01/01/2011 and 11/30/2022

Brief summary: Carbapenemase-producing Enterobacteriaceae (CPE) infections are emerging infections that pose a therapeutic challenge. These infections mainly occur in patients with prolonged hospitalization and repeated exposure to antibiotics. Certain strains, notably VIM-producing strains, may remain sensitive to carbapenems. CPE VIM strains are rare in France, but represent the main CPE strains in many countries. They are historically the main type of carbapenemases isolated at the Strasbourg University Hospital.

Detailed description: The circulation of multi-antibiotic-resistant bacterial strains is significant at the Strasbourg University Hospital and the investigators wish to report their local experience in the use of carbapenems in infections with enterobacteria producing carbapenemase type VIM.

Eligibility criteria: Inclusion Criteria:

* Adult patient (≥18)
* Treated at the HUS for a VIM-producing enterobacteria infection between 01/01/2011 and 11/30/2022
* Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes.

Exclusion Criteria:

* Patient having expressed his opposition to the retrospective reuse of his data for scientific research purposes.

Primary outcomes:
measure: Mortality at 28 days
timeFrame: Mortality at 28 days after infection
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT04510753: Data Collection of Arterial Line Waveform and BP Values
Official title: Evaluation of Sensifree's Algorithm for Continuous Blood Pressure Measurements Based on a PPG Sensor's Signal Compared to Invasive Radial Arterial Line
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Blood Pressure Measurement
Lead sponsor: Sensifree Ltd.
Sponsor class: INDUSTRY
First posted: 2020-08-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients scheduled for elective surgery involving placement of radial artery A-line for BP monitoring

Brief summary: Collect continuous systolic and diastolic blood pressure values and waveforms as recorded by an arterial line catheter and by non-invasive blood pressure (NIBP) and to collect Photoplethysmogram Pulse Oximetry (PPG) waveform in order to optimize the Sensifree algorithm.

Detailed description: Sensifree is developing a continuous non-invasive blood pressure measurement system, that uses a fingertip PPG sensor as a signal source. The system provides systolic, diastolic and mean arterial pressure values, for use in hospitals and other clinical settings. The PPG waveform is analyzed by a proprietary software algorithm, calculating BP values.

The current best method to obtain similar information is by using an Arterial line catheter which will serve as a reference device. In this study, the sponsor aims to prospectively collect continuous radial arterial line \& PPG waveforms, as well as NIBP data over the period of the surgery in order to test and refine the algorithm.

Eligibility criteria: Inclusion Criteria:

1. Signed inform consent
2. Age 18 or greater
3. Elective surgery that requires invasive BP monitoring (A-line)

Exclusion Criteria:

1. Emergency surgery
2. A-line not inserted
3. Informed consent not signed

Primary outcomes:
measure: Comparison of BP values between a PPG sensor based device and an arterial line
timeFrame: The length of each procedure, typically up to 8 hours
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: San Francisco Veterans Affairs Medical Center
state: California
Study officials:
affiliation: San Francisco Veterans Affairs Medical Center
name: Arthur Wallace, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01581853: Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
Official title: Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: HIV
Keywords: HIV
AIDS
MONOTHERAPY
PILOT
LOPINAVIR/RITONAVIR
Lead sponsor: Hospital Universitari de Bellvitge
Sponsor class: OTHER
First posted: 2012-04-20
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Lopinavir/ritonavir monotherapy is currently a well known and widely used strategy, while Lopinavir/ritonavir 800/200 mg once a day in a triple-therapy was approved a few years ago. The purpose of this study is to evaluate efficacy and safety of Lopinavir/ritonavir 800/200 mg monotherapy once a day.


Eligibility criteria: Inclusion Criteria:

* Patients older than 18, HIV positive
* Patients receiving a monotherapy regimen (Lopinavir/ritonavir twice daily)during the last 6 months
* Undetectable viral load (\<40 copies/ml) during the last 6 months
* Patients that accept participation in the study and sign the Informed Consent Form
* Childbearing females with negative pregnancy tests and using appropriate contraceptive measures

Exclusion Criteria:

* Opportunistic disease, cancer or any other active disease with specific treatment
* Active addiction to illegal drugs or active use of psychotropic drugs
* Mental retardation diagnosis, or mental dementia or severe psychiatric disorder (excluding major depression disorder solved \> 3 months)
* Females who are breastfeeding or pregnant

Primary outcomes:
measure: plasma viral load <40 copies/mL
timeFrame: Week 48
Secondary outcomes:
measure: Stability in the plasma levels of Lopinavir/ritonavir during all study visits
timeFrame: Weeks 4, 8, 12, 16, 24, 36 and 48
measure: Tolerability
timeFrame: Weeks 4, 8, 12, 16, 24, 36 and 48
measure: Adherence
timeFrame: Weeks 4, 8, 12, 16, 24, 36 and 48
measure: Satisfaction
timeFrame: Weeks 4, 8, 12, 16, 24, 36 and 48
measure: - Efficacy in CSF
timeFrame: At least 4 weeks on study treatment
Other outcomes:
Locations:
city: Bercelona
country: Spain
facility: Hospital del Mar
state: Barcelona
city: Hospitalet de Llobregat
country: Spain
facility: Hospital Universitary de Bellvitge
state: Barcelona
Study officials:
affiliation: Hospital Universitari de Bellvitge
name: Daniel Podzamczer, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital del Mar
name: Hernando Knobel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06625853: XP-Endo Finisher on Postoperative Pain in Retreatment Cases Using Mtwo R Files
Official title: Supplementary Use of the XP-Endo Finisher on Postoperative Pain in Retreatment Cases Using Mtwo R Files (Randomized Clinical Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Pain
Endodontically Treated Teeth
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2024-10-03
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Introduction: Postoperative pain is one of the most critical issues in our daily practice. , postoperative pain control is essential for patient satisfaction and comfort. When primary root canal treatment fails, root canal retreatment aims to heal apical periodontitis.

Aim of study: To compare between postoperative pain (POS) after endodontic retreatment using NI-TI rotary files Mtwo R alone and in conjunction with XP endo finisher .

Materials and Methods: This research is a randomized clinical trial conducted in a parallel design on 50 patients needing retreatment. They will be divided into two groups, group 1 retreatment with Mtwo R, group 2 retreatment with Mtwo R followed by Xp - Endo finisher. Postoperative pain levels will be evaluated at 24 hours, 48 hours, 72 hours, and 7 days following the removal of the obturation mat erial. The assessment of pain will be done through clinical examination, The Defense and veterans pain rating scale (DVPRS) and by the intake of pain killer


Eligibility criteria: Inclusion Criteria:

* Teeth with mature apices.
* Patients with no systemic diseases.
* No analgesic, anti-inflammatory, or antibiotic intake during 7 days before treatment.
* Teeth showing failure of initial root canal treatment and radiograph evidence of periapical bone destruction

Exclusion Criteria:

* Multi rooted teeth.
* Teeth with open apices.
* Teeth with cracks, calcification, root caries, fractures, external or internal resorption.
* Allergies to local anesthetic agents.
* Presence of severe pain and/or acute apical abscesses

Primary outcomes:
measure: Change in pain
timeFrame: 24-hours,48-hours,72hours and 7 days
Secondary outcomes:
measure: change in analgesics intake according to severity of pain according to WHO Analgesic Ladder
timeFrame: 24-hours,48-hours,72hours and 7 days
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Alexandria Faculty of Dentistry
Study officials:
References:
Clinical trial NCT03372577: Mindfulness-based Sex Therapy on Patients With Takotsubo Cardiomyopathy
Official title: Mindfulness-based Sex Therapy on Patients With Takotsubo Cardiomyopathy Among Iranian Women
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Takotsubo Cardiomyopathy
Sexual Dysfunction
Lead sponsor: Qazvin University Of Medical Sciences
Sponsor class: OTHER
First posted: 2017-12-13
Enrollment: 450
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Takotsubo cardiomyopathy (TC) is a type of non-ischemic cardiomyopathy in which there is a sudden temporary weakening of the myocardium. . In a recent study, women report more sexual dysfunction than men after 1 year after TC. Despite that a number of studies have assessed female sexual dysfunction (FSD) for TC , there is no information regarding prevalence and associated factors on FSD in women with TC. However, in a recent study on Iranian female patients with TC, more than 77% of these patients suffered from FSD. This study is aimed to assess the effectiveness of a Mindfulness-based Sex Therapy on Patients With TC.


Eligibility criteria: Inclusion Criteria:

* aged 18 years old at least
* confirmed diagnosis of TC by a cardiologist according Mayo Clinic diagnostic criteria; an acute left ventricular apical ballooning of unknown cause
* willingness to partaking for the duration of the trial
* a basic fluency in Persian
* living with a partner/spouse

Exclusion Criteria:

* cognitive disability
* having acute myocardial infarction
* cerebrovascular disease
* pheochromocytoma and viral or idiopathic myocarditis
* , participating in another RCT

Primary outcomes:
measure: Sexual functioning
timeFrame: changes from baseline, 1 Months ,6 months, 12 months and 18 months
measure: Sexual Distress
timeFrame: changes from baseline, 1 Months ,6 months, 12 months and 18 months
measure: Intimacy
timeFrame: changes from baseline, 1 Months ,6 months, 12 months and 18 months
Secondary outcomes:
measure: Mindfulness
timeFrame: changes from baseline, 1 Months ,6 months, 12 months and 18 months
measure: Marital satisfaction
timeFrame: changes from baseline, 1 Months ,6 months, 12 months and 18 months
measure: Psychological distress
timeFrame: changes from baseline, 1 Months ,6 months, 12 months and 18 months
measure: Rumination
timeFrame: changes from baseline, 1 Months ,6 months, 12 months and 18 months
measure: Emotion regulation
timeFrame: changes from baseline, 1 Months ,6 months, 12 months and 18 months
measure: quality of life
timeFrame: changes from baseline, 1 Months ,6 months, 12 months and 18 months
measure: Social Support
timeFrame: changes from baseline, 1 Months ,6 months, 12 months and 18 months
measure: Sense of Coherence
timeFrame: changes from baseline, 1 Months ,6 months, 12 months and 18 months
Other outcomes:
Locations:
city: Qazvin
country: Iran, Islamic Republic of
facility: Booali Sina Hospital
Study officials:
References:
Clinical trial NCT01848977: Comparison of Two Devices Using Near-infra Red Spectroscopy During a Vascular Occlusion Test
Official title: Comparison of Two Devices Using Near-infra Red Spectroscopy for the Measurement of Tissue Oxygenation During a Vascular Occlusion Test (INVOS® Versus Inspectra™)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Measures
near-Infrared spectroscopy
ischemia
reperfusion
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2013-05-08
Enrollment: 20
Sex: ALL
Minimum age (years): 26
Maximum age (years): 41
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Tissue oxygen saturation is non-invasively measured using near-infrared spectroscopy, by two device, INVOS®(somanetics Corporation, USA ) and InSpectra™ (Hutchinson Technology, USA). Each probes are attached to both thenar muscles and vascular occlusion test (VOT) is performed. The investigators will compare the Invos® data to InSpectra™ to investigate whether tissue oxygen saturation values by INVOS® can substitute for InSpectra™.

Detailed description: Tissue oxygen saturation is non-invasively measured using near-infrared spectroscopy, by two device, INVOS®(somanetics Corporation, USA ) and InSpectra™ (Hutchinson Technology, USA). InSpectra™ was introduced later than INVOS®.

With InSpectra™, clinicians have used a vascular occlusion test (VOT) to evaluate dynamic changes in tissue oxygen saturation during ischemia and reperfusion, and thus, microcirculatory function. There have been little data about VOT using INVOS®, although it is more popular device.

We hypothesized that there would be a difference between the values from INVOS® and InSpectra™. The aim of this study is to evaluate changes in tissue oxygen saturation in the thenar muscle during VOT using INVOS® and comapre it to InSpectra™ in a normal population.

Eligibility criteria: Inclusion Criteria:

* healthy subject

Exclusion Criteria:

* age under 18 years old
* with arteriovenous fistula
* with peripheral vessel disease
* taking vasoactive drug
* with a skin ailment
* with HTN, DM
* with diagnosed heart disease

Primary outcomes:
measure: Change of Tissue Oxygenation Value During Ischemia and Reperfusion Period Until Basline Value Was Achieved
timeFrame: Until basline tissue oxygenation value was achieved
measure: Sum of Tissue Oxygenation Value Which Above Basline Value After Reperfusion Period Until Basline Value Was Achieved
timeFrame: Until basline tissue oxygenation value was achieved
Secondary outcomes:
measure: Baseline, Miminum and Maximum Tissue Oxygenation Value Measured by INVOS® (SrO2) Until Basline Value Was Achieved
timeFrame: Until basline tissue oxygenation value was achieved
Other outcomes:
Locations:
Study officials:
affiliation: Seoul National University Hospital
name: Jin-Tae Kim, Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00229177: Study of ONO-2506 in Patients With Acute Ischemic Stroke
Official title: Controlled Study of ONO-2506 in Patients With Acute Ischemic Stroke
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Stroke
Keywords: ONO-2506
stroke
Acute ischemic stroke
Lead sponsor: Ono Pharmaceutical Co. Ltd
Sponsor class: INDUSTRY
First posted: 2005-09-29
Enrollment: 757
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the efficacy and safety of ONO-2506 compared to placebo in patients with acute ischemic stroke.


Eligibility criteria: Inclusion Criteria:

1. Subjects who have a clinical diagnosis of acute ischemic stroke
2. Subjects within 72 hours after onset of the stroke
3. Other inclusion criteria may apply.

Exclusion Criteria:

1. Subjects who are scheduled to have surgical operations likely to affect the prognosis (including intravascular surgery and circulatory reconstruction)
2. Subjects who are pregnant or lactating, or who have child-bearing potential, or who wish to become pregnant.
3. Other exclusion criteria may apply.

Primary outcomes:
measure: Modified Rankin Scale at 90 days
timeFrame: 90 days
Secondary outcomes:
measure: Modified Rankin Scale at 30 days
timeFrame: 30 days
measure: National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI), and Glasgow Outcome Scale (GOS) at 90 days
timeFrame: 90 days
Other outcomes:
Locations:
city: Chubu
country: Japan
facility: Chubu Region Facility
city: Chugoku
country: Japan
facility: Chugoku Region Facility
city: Hokkaido
country: Japan
facility: Hokkaido Region Facility
city: Hokuriku
country: Japan
facility: Hokuriku Region Facility
city: Kanto
country: Japan
facility: Kanto Region Facility
city: Kinki
country: Japan
facility: Kinki Region Facility
city: Kyushu
country: Japan
facility: Kyushu Region Facility
city: Shikoku
country: Japan
facility: Shikoku Region Facility
city: Tohuku
country: Japan
facility: Tohoku Region Facility
Study officials:
affiliation: Ono Pharmaceutical Co. Ltd
name: Project Leader, Development Planning
role: STUDY_DIRECTOR
References:
Clinical trial NCT04428177: Coronary Calcification Study - Intravascular Lithotripsy for Calcified Lesions
Official title: Intravascular Lithotripsy in the Treatment of Calcified Coronary Lesions - Coronary Calcification Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Coronary Artery Calcification
Keywords: Coronary Artery Calcification
Intravascular Lithotripsy
Lead sponsor: University Hospital Ostrava
Sponsor class: OTHER
First posted: 2020-06-11
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this prospective randomised study is to compare the safety and efficacy of novel intravascular lithotripsy (IVL) to the standard therapy of calcified coronary lesions.

Detailed description: The study will include a total of 40 patients with calcified coronary lesions who will be randomised 1:1 to the treatment with IVL (Shockwave; Shockwave Medical, Inc, Santa Clara, USA) or the standard therapy (non-compliat high-pressure or Scoreflex predilatation, rotational atherectomy, etc). Appropriate preparation of the lesions will be followed by DES implantation.

Eligibility criteria: Inclusion Criteria:

* Age ≥18 years
* Informed, written consent by the patient
* Ability to comply fully with the study protocol
* Negative pregnancy test (and effective contraception) in women with childbearing potential

Angiographic inclusion criteria:

* Native coronary artery lesion with diameter stenosis ≥50% suitable for PCI
* Heavy calcification, defined as calcification within the lesion on both sides of the vessel assessed during angiography
* Reference vessel diameter (RVD) ≥2.5 mm with lesion length \<32 mm
* TIMI flow 3 of the target vessel at baseline
* No visible thrombus at target lesion site

Exclusion Criteria:

* Cardiogenic shock or haemodynamic instability requiring mechanical circulatory support
* Active malignancy or other comorbidities with a life expectancy of 12 months
* Limited the possibility of control coronaro angiography (e.g., advanced renal failure)
* Known allergy to contrast agents (that cannot be adequately premedicated) or required concomitant dual antiplatelet therapy
* Current problems with substance abuse (e.g., alcohol or drugs)
* Subject is participating in another investigational drug or device clinical study

Primary outcomes:
measure: Minimal lumen diamether (MLD)
timeFrame: 1 year
measure: Late luemn loss (LLL)
timeFrame: 1 year
Secondary outcomes:
measure: Binary in-stent restenosis
timeFrame: 1 year
measure: Major adverse cardiac events (MACE)
timeFrame: 1 year
Other outcomes:
measure: Angiographic success
timeFrame: up to end of the procedure, an average of 2 hours
measure: Clinical success
timeFrame: up to discharge, an average of 3 days
Locations:
city: Ostrava
country: Czechia
facility: Department of Cardiovascular Diseases, University Hospital
state: Česká Republika
Study officials:
References:
Clinical trial NCT04351477: Mechanical Massage Chair on Musculoskeletal Pain Improvement
Official title: The Effect of Mechanical Massage Chair on Musculoskeletal Pain Improvement for Endoscopists and Endoscopy Nurses
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Massage Therapy
Keywords: massage chair
mulsculoskeletal pain
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2020-04-17
Enrollment: 25
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomized, open-label, cross-over study
Primary purpose: OTHER

Brief summary: The effect of mechanical massage chair on musculoskeletal pain improvement for endoscopists and endoscopy nurses

Detailed description: Randomized, open-label, cross-over study

1. 1st phase Massage chair group (20 minutes/session, 3 sessions/week, 3 weeks), vs. control (no use of massage chair)
2. Wash-out period (9 weeks)
3. 2nd phase (cross-over) Massage chair group (20 minutes/session, 3 sessions/week, 3 weeks), vs. control (no use of massage chair)

   * Msculoskeletal pain questionnaires (VAS, NDI, SPADI)

1) 1st phase: at baseline, 1.5 wk, 3 wk 2) 2nd phase: at baseline, 1.5 wk, 3 wk, 9wk after the end of treatment

Eligibility criteria: Inclusion Criteria:

* Endoscopists or endoscopic nurses working at Seoul National University Hospital Gangnam Center

Exclusion Criteria:

* Spine disease, skin disease, acute inflammation, electrical heart device, thromboembolism, fracture, osteoporosis, varicose vein
* Pregnancy

Primary outcomes:
measure: Visual analogue scale
timeFrame: The change of VAS value at baseline, 1.5 week, 3 weeks during treatment, and 9 weeks after treatment
Secondary outcomes:
measure: Neck disability index (NDI)
timeFrame: The change at baseline, 1.5 week, 3 weeks during treatment, and 9 weeks after treatment
measure: Shoulder pain and disability index (SPADI)
timeFrame: The change at baseline, 1.5 week, 3 weeks during treatment, and 9 weeks after treatment
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Healthcare System Gangnam Center, Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital Gangnam Center
name: Min-Sun Kwak, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: